What is the recommended treatment for acute calcium pyrophosphate crystal arthritis (pseudogout)?

Treatment of Acute Pseudogout (Calcium Pyrophosphate Crystal Arthritis)

For acute pseudogout, start with joint aspiration plus intra-articular corticosteroid injection combined with ice application and temporary rest—this approach alone is sufficient for most patients and carries the highest strength of recommendation. 1

First-Line Treatment Algorithm

Monoarticular or Oligoarticular Disease (Preferred Approach)

• Joint aspiration (confirms diagnosis, excludes septic arthritis, provides symptom relief)
• Intra-articular long-acting corticosteroid injection immediately after aspiration
• Ice or cool packs to the affected joint
• Temporary rest with weight restriction
• This combination has a 95% strength of recommendation and may be sufficient without systemic therapy 1

When Systemic Therapy is Needed

Choose based on patient age, comorbidities, and renal function:

Option 1: Low-Dose Colchicine (Safer in Elderly)

• Dosing: 0.5 mg 3-4 times daily (with or without 1 mg loading dose)
• NOT the traditional high-dose regimen (which causes 100% side effect rate)
• Effective but limited by diarrhea, especially problematic in elderly patients with renal impairment 1

Option 2: NSAIDs (If No Contraindications)

• Always combine with gastroprotective agent (proton pump inhibitor)
• Avoid in elderly patients with:
  • Chronic kidney disease
  • Cardiovascular disease
  • History of GI bleeding
• NSAIDs and colchicine have similar efficacy (79% strength of recommendation) but high toxicity risk in older adults 1

Polyarticular Disease or When Intra-articular Injection Not Feasible

Systemic corticosteroids are the preferred alternative:

Option 1: Oral Corticosteroids

• Short tapering course (e.g., prednisone 30-40 mg daily, taper over 7-10 days)
• 87% strength of recommendation 1

Option 2: Parenteral Corticosteroids

• Intramuscular betamethasone 7 mg (single injection), OR
• Intravenous methylprednisolone 125 mg (single injection)
• More effective than NSAIDs for rapid pain control on day 1 (NNT=3)
• Well-tolerated with minimal side effects 1

Option 3: ACTH (Adrenocorticotropic Hormone)

• 40-80 units IM/IV/SC three times
• Resolves attacks in average 4.2 days
• Consider when corticosteroids contraindicated 1

Critical Pitfalls to Avoid

1. Never Use High-Dose Colchicine Regimen

The traditional regimen (0.5 mg every 2 hours until diarrhea) causes 100% side effect rate and is no longer recommended 1

2. Never Use Intravenous Colchicine

Despite historical use, IV colchicine carries high risk of serious toxicity and fatality—it's no longer used in most countries 1

3. Exercise Extreme Caution with NSAIDs in Elderly

Pseudogout predominantly affects older patients who often have:

• Chronic renal impairment
• Cardiovascular comorbidities
• Polypharmacy with drug interaction risks
• High bleeding risk 1

4. Don't Miss Septic Arthritis

Always aspirate joint fluid before treatment to:

• Confirm CPP crystals (rhomboid-shaped, weakly positive birefringent)
• Exclude bacterial infection with Gram stain and culture
• This is especially critical in prosthetic joints 2

Special Populations

Patients with Multiple Contraindications

When NSAIDs and colchicine are both contraindicated (common in elderly):

• Systemic corticosteroids become first-line systemic therapy 1
• Consider anakinra (IL-1 inhibitor) for refractory cases 3, 4

Recurrent Acute Attacks (Prophylaxis)

If patient has frequent flares:

• Low-dose colchicine 0.5-1 mg daily reduces attack frequency by 69% (from 3.2 to 1.0 attacks/year) 1
• Alternative: Low-dose NSAID with gastroprotection (81% strength of recommendation) 1

Evidence Quality Context

The EULAR guidelines 1 represent the highest quality evidence available, though most recommendations are extrapolated from gout studies (Level Ib-IV evidence). The strongest recommendation (95% confidence) supports the intra-articular approach, reflecting both clinical expertise and safety profile. Recent research 3, 4 confirms these approaches remain current, with ongoing trials investigating IL-1 and IL-6 inhibitors for refractory disease.

Bottom line: Prioritize local therapy (aspiration + intra-articular steroids) over systemic medications whenever anatomically feasible—it's safer, equally effective, and avoids systemic toxicity in this vulnerable elderly population.